To the full analysis
Nutex Health stock: growth
NUTXNutex Health reported $875.26M in revenue for fiscal 2025, up 82.4% on the prior year, up 26.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
no data
Earnings (Annual rate)
35.5%
per year from 2008 to 2025, per share −25.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2008 | |
|---|---|---|---|
| Revenue | 26.1% | no data | no data |
| Revenue per share | 16.6% | no data | no data |
| Earnings | −7.8% | 96.2% | 35.5% |
| Earnings per share | −14.7% | 75.3% | −25.1% |
| Free cash flow | 57.3% | 136.5% | no data |
| Free cash flow per share | 45.4% | 111.3% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2008 | $0 | $403.39K | −$268.61K |
| 2009 | $220.47K | $605.29K | −$981.87K |
| 2010 | $1.27M | $158.14K | −$894.79K |
| 2011 | $2.55M | −$383.39K | −$683.97K |
| 2012 | $1.59M | −$1.62M | −$526.74K |
| 2013 | $1.46M | $250.49K | −$183.15K |
| 2014 | $1.07M | −$684.34K | $163.78K |
| 2015 | $0 | $83.81K | $44.91K |
| 2016 | $0 | −$7.43M | −$274.22K |
| 2017 | $23.17K | $582.06K | −$714.62K |
| 2018 | $1.37M | −$2.81M | −$480.05K |
| 2019 | $97.06M | $20.92M | −$20.15M |
| 2020 | $274.03M | $105.97M | $25.48M |
| 2021 | $331.53M | $132.59M | $136.51M |
| 2022 | $219.29M | −$424.78M | $35.97M |
| 2023 | $247.65M | −$45.79M | −$8.24M |
| 2024 | $479.95M | $52.18M | $20.85M |
| 2025 | $875.26M | $70.79M | $245.6M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.